8-KRegulation FD

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Jan 8, 2024)

Filed January 8, 2024For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced on January 8, 2024, a significant development: the execution of a definitive agreement to acquire Axonics, Inc. This strategic move is expected to bolster Boston Scientific's product portfolio and market presence. The acquisition is anticipated to close in the first half of 2024, contingent upon the satisfaction of customary closing conditions. Investors should note that the company has also released an investor presentation accompanying this announcement. While the press release and presentation offer details on the transaction, they also contain forward-looking statements. Management cautions that actual results could differ materially from these projections due to various risks and uncertainties, including integration challenges, regulatory approvals, market acceptance, and broader economic conditions. Interested parties are advised to review the full 8-K filing for a comprehensive understanding of the transaction and associated risks.

Key Highlights

  • 1Boston Scientific (BSX) has entered into a definitive agreement to acquire Axonics, Inc.
  • 2The acquisition is expected to close in the first half of 2024.
  • 3Customary closing conditions, including regulatory approvals, must be met for the transaction to be completed.
  • 4An investor presentation has been made available to provide further details on the transaction.
  • 5The filing includes cautionary statements regarding forward-looking statements and potential risks.
  • 6The company highlights potential impacts on its business strategy, product launches, and financial results.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce Boston Scientific's definitive agreement to acquire Axonics, Inc. It also provides context by referencing an accompanying press release and investor presentation that detail the transaction.

The acquisition of Axonics is expected to close in the first half of 2024, subject to the satisfaction of customary closing conditions.

Yes, the filing includes a cautionary statement about forward-looking statements. Potential risks include challenges in integrating Axonics' operations, obtaining necessary regulatory approvals, market acceptance of products, and general economic or competitive pressures. Investors are encouraged to review the full risk factors outlined in Boston Scientific's most recent 10-K filing.

Boston Scientific has attached a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) to this 8-K filing, which are available on their website. These documents provide further details regarding the transaction.